Alexion to start Soliris in COVID-19 Phase II trial in next few days
By MYBRANDBOOK
Alexion Pharmaceuticals is revving up to enter the COVID-19 drug development race with Soliris (eculizumab), a drug that is already approved for other indications, a source familiar with the trial told Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company.
Castañeda comments: “The source explained that the idea behind Soliris is that the drug impacts the complement system, which could help reduce organ damage in severe COVID-19 patients.”
When asked to comment, an Alexion spokesperson pointed Castañeda to a media release stating how the company is interested in the potential use of Soliris in COVID-19 due to preclinical rationale that suggests it could be used in a subset of patients who have coronaviral infection and severe pneumonia or acute respiratory distress syndrome. Alexion is providing Soliris for experimental emergency treatment for a small number of patients with COVID-19 infection and severe pneumonia, it states.
Soliris made $3.95bn in 2019, as per SEC filings. It was first approved by the US Food and Drug Administration (FDA) in May 2007 for the rare blood disease paroxysmal nocturnal hemoglobinuria and subsequently approved in haemolytic uremic syndrome and myasthenia gravis in September 2011 and October 2017, respectively.
Castañeda continues: “This planned COVID-19 Phase II study is on the heels of a ten-patient, single-site, proof-of-concept trial, which started ten days ago, and data is expected to be revealed sometime this week, the source noted. While he declined to detail the status of these ten patients, he noted the patients improved in general.”
GlobalData’s COVID-19 Intelligence Dashboard shows that there are 623 clinical trials across the globe that are either planned or ongoing.
Nazara and ONDC set to transform in-game monetization with ‘
Nazara Technologies has teamed up with the Open Network for Digital Comme...
Jio Platforms and NICSI to offer cloud services to government
In a collaborative initiative, the National Informatics Centre Services In...
BSNL awards ₹5,000 Cr Project to RVNL-Led Consortium
A syndicate led by Rail Vikas Nigam Limited (abbreviated as RVNL), along wi...
Pinterest tracks users without consent, alleges complaint
A recent complaint alleges that Pinterest, the popular image-sharing platf...
EXIDE INDUSTRIES LTD.
TALLY SOLUTIONS PVT. LTD.
TP-LINK INDIA PVT. LTD.
POLYCAB INDIA PVT. LTD
ICONS OF INDIA : VINAY SINHA
Vinay Sinha is the Managing Director of Sales for the India Mega Regio...
Icons Of India : CP Gurnani
Former Managing Director and CEO of the well-known IT service company ...
ICONS OF INDIA : RAJIV MEMANI
As Chair of the EY Global Emerging Markets Committee, Rajiv connects e...
CERT-IN - Indian Computer Emergency Response Team
CERT-In is a national nodal agency for responding to computer security...
GSTN - Goods and Services Tax Network
GSTN provides shared IT infrastructure and service to both central and...
ECIL - Electronics Corporation of India Limited
ECIL is distinguished by its diverse technological capabilities and it...
Indian Tech Talent Excelling The Tech World - Shantanu Narayen, CEO- Adobe Systems Incorporated
Shantanu Narayen, CEO of Adobe Systems Incorporated, is renowned for h...
Indian Tech Talent Excelling The Tech World - Sundar Pichai, CEO- Alphabet Inc.
Sundar Pichai, the CEO of Google and its parent company Alphabet Inc.,...
Indian Tech Talent Excelling The Tech World - Steve Sanghi, Executive Chair, Microchip
Steve Sanghi, the Executive Chair of Microchip Technology, has been a ...